RECORD // Company

BioCardia, Inc.

Formerly: Tiger X Medical, Inc.; Cardo Medical, Inc.; CLICKNSETTLE COM INC; NAM CORP

Built 2026-11-22T03:20:32Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
  • BioCardia, Inc. · legal entity in this company's GLEIF ownership tree (LEI 5493003EDBXRQRW22O75)
SEC EDGAR (1)
Matched by name only, not merged (7)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Biocardia Inc · Ca business · same registered legal name as 'BioCardia, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BIOCARDIA INC · Ca payments · same registered legal name as 'BioCardia, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BioCardia, Inc. · Ctgov · same registered legal name as 'BioCardia, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BIOCARDIA, INC. · East licences · same registered legal name as 'BioCardia, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BIOCARDIA INC · Epa echo · same registered legal name as 'BioCardia, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BIOCARDIA INC · Epa echo · same registered legal name as 'BioCardia, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • BIOCARDIA, INC. · USAspending · same registered legal name as 'BioCardia, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001437749-26-036559

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-1,817,0003 months ended 2026-09-3010-Q2026-11-120001437749-26-0365592026-11-22 03:20 UTCReport an error
Cash and cash equivalents$2,224,000at 2026-09-3010-Q2026-11-120001437749-26-0365592026-11-22 03:20 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0000925741
Ticker
BCDA
EIN
232753988
CUSIP
09060U606
Record ID
sx:sec:0000925741

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

34 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-22 03:20 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-20SEC EDGAR company profile2026-11-22 03:20 UTCReport an error
State of incorporationDE2026-11-20SEC EDGAR company profile2026-11-22 03:20 UTCReport an error
Fiscal year end (MMDD)12312026-11-20SEC EDGAR company profile2026-11-22 03:20 UTCReport an error
Business address320 SOQUEL WAY, SUNNYVALE, CA, 940852026-11-20SEC EDGAR company profile2026-11-22 03:20 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-22 03:20 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$02025-12-3110-K, XBRL RevenueFromContractWithCustomerIncludingAssessedTax2026-11-22 03:20 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-8,228,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 03:20 UTCReport an error
Total assets (at 2025-12-31)$3,413,0002025-12-3110-K, XBRL Assets2026-11-22 03:20 UTCReport an error
Stockholders' equity (at 2025-12-31)$895,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 03:20 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$2,496,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 03:20 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-7,436,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 03:20 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$7,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 03:20 UTCReport an error
Remaining performance obligation (at 2025-12-31)$02025-12-3110-K, XBRL RevenueRemainingPerformanceObligation2026-11-22 03:20 UTCReport an error
Operating lease liabilities (at 2025-12-31)$528,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 03:20 UTCReport an error
Form D total offering amount (D filed 2019-01-07)$4,000,0002019-01-07D2026-11-22 03:20 UTCReport an error
Form D total amount sold (D filed 2019-01-07)$4,000,0002019-01-07D2026-11-22 03:20 UTCReport an error
Form D industry groupBiotechnology2019-01-07D2026-11-22 03:20 UTCReport an error
Form D revenue rangeDecline to Disclose2019-01-07D2026-11-22 03:20 UTCReport an error
Form D date of first sale2018-12-242019-01-07D2026-11-22 03:20 UTCReport an error
8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (filed 2026-11-20)On November 20, 2026, BioCardia, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s stockholders’ equity of $835,000 as of September 30, 2026, it is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The Company has until January 4, 2027 to provide Nasdaq with a plan to regain compliance with the foregoing listing requirement. If the Company’s plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days from November 20, 2026…2026-11-20SEC EDGAR 8-K 0001437749-26-037908 (text as filed, excerpt)2026-11-22 03:20 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-12)On November 12, 2026, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including the Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such…2026-11-12SEC EDGAR 8-K 0001437749-26-036574 (text as filed, excerpt)2026-11-22 03:20 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-06)On November 6, 2026, BioCardia, Inc. issued a press release announcing completion of clinical consultation process with Japan's PMDA for CardiAMP Cell Therapy System, advancing toward submission of marketing approval application. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K. The information furnished pursuant to this Item 8.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under…2026-11-06SEC EDGAR 8-K 0001437749-26-035408 (text as filed, excerpt)2026-11-22 03:20 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-19)On October 19, 2026, BioCardia, Inc. issued a press release announcing FDA Acceptance of De Novo Pre-Submission Package for Helix Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K. The information furnished pursuant to this Item 8.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities…2026-10-19SEC EDGAR 8-K 0001437749-26-032887 (text as filed, excerpt)2026-11-22 03:20 UTCReport an error
Largest institutional holder #1 (13F as filed): CITIGROUP INC$493,0172026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:20 UTCReport an error
Largest institutional holder #2 (13F as filed): CM Management, LLC$372,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:20 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$154,4932026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:20 UTCReport an error
Largest institutional holder #4 (13F as filed): Pingora Partners LLC$149,2742026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:20 UTCReport an error
Largest institutional holder #5 (13F as filed): UBS Group AG$96,2482026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:20 UTCReport an error
Largest institutional holder #6 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$82,6622026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:20 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD FIDUCIARY TRUST CO$82,1752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:20 UTCReport an error
Largest institutional holder #8 (13F as filed): SUSQUEHANNA INTERNATIONAL GROUP, LLP$48,1232026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:20 UTCReport an error
Largest institutional holder #9 (13F as filed): BROWN ADVISORY INC$44,0672026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:20 UTCReport an error
Largest institutional holder #10 (13F as filed): COMMONWEALTH EQUITY SERVICES, LLC$28,9902026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:20 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.